Alto Neuroscience (ANRO) Competitors $3.20 +0.09 (+2.72%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$3.13 -0.07 (-2.22%) As of 02/21/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ANRO vs. CMRX, ACB, ANNX, TRML, MBX, CYRX, CRVS, PRME, MNPR, and ATYRShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Chimerix (CMRX), Aurora Cannabis (ACB), Annexon (ANNX), Tourmaline Bio (TRML), MBX Biosciences (MBX), Cryoport (CYRX), Corvus Pharmaceuticals (CRVS), Prime Medicine (PRME), Monopar Therapeutics (MNPR), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. Chimerix Aurora Cannabis Annexon Tourmaline Bio MBX Biosciences Cryoport Corvus Pharmaceuticals Prime Medicine Monopar Therapeutics Atyr PHARMA Alto Neuroscience (NYSE:ANRO) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability. Does the media refer more to ANRO or CMRX? In the previous week, Chimerix had 22 more articles in the media than Alto Neuroscience. MarketBeat recorded 25 mentions for Chimerix and 3 mentions for Alto Neuroscience. Chimerix's average media sentiment score of 0.60 beat Alto Neuroscience's score of 0.07 indicating that Chimerix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Chimerix 9 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is ANRO or CMRX more profitable? Alto Neuroscience's return on equity of -49.28% beat Chimerix's return on equity.Company Net Margins Return on Equity Return on Assets Alto NeuroscienceN/A -49.28% -33.52% Chimerix N/A -50.78%-44.94% Which has better valuation & earnings, ANRO or CMRX? Alto Neuroscience has higher earnings, but lower revenue than Chimerix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlto NeuroscienceN/AN/A-$36.31MN/AN/AChimerix$320K1,451.41-$82.10M-$0.94-5.49 Do institutionals & insiders hold more shares of ANRO or CMRX? 45.4% of Chimerix shares are owned by institutional investors. 13.1% of Chimerix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend ANRO or CMRX? Alto Neuroscience presently has a consensus target price of $20.00, suggesting a potential upside of 524.02%. Chimerix has a consensus target price of $9.00, suggesting a potential upside of 74.28%. Given Alto Neuroscience's higher possible upside, equities analysts plainly believe Alto Neuroscience is more favorable than Chimerix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.63Chimerix 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer ANRO or CMRX? Chimerix received 382 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 82.35% of users gave Alto Neuroscience an outperform vote while only 63.97% of users gave Chimerix an outperform vote. CompanyUnderperformOutperformAlto NeuroscienceOutperform Votes1482.35% Underperform Votes317.65%ChimerixOutperform Votes39663.97% Underperform Votes22336.03% SummaryChimerix beats Alto Neuroscience on 7 of the 13 factors compared between the two stocks. Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeurosciencePharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$86.44M$7.04B$5.77B$20.07BDividend YieldN/A2.87%4.78%3.65%P/E RatioN/A6.1326.4634.90Price / SalesN/A309.83453.2515.64Price / CashN/A67.8344.0420.85Price / BookN/A6.747.634.92Net Income-$36.31M$138.11M$3.18B$1.02B7 Day Performance-4.75%-2.43%-1.91%-1.05%1 Month Performance-29.58%-1.91%-0.19%-1.09%1 Year Performance-75.35%-5.03%16.70%13.70% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience1.762 of 5 stars$3.21+2.7%$20.00+524.0%-76.2%$86.44MN/A0.00N/ACMRXChimerix4.2604 of 5 stars$4.06-3.6%$8.50+109.4%+333.9%$365.14M$159,000.00-4.3290Analyst ForecastAnalyst RevisionNews CoverageACBAurora Cannabis0.5175 of 5 stars$6.61+9.6%N/A+73.2%$362.63M$200.35M132.231,073Gap UpANNXAnnexon2.5591 of 5 stars$3.40-1.2%$15.80+364.7%-42.8%$362.41MN/A-3.2460News CoverageGap UpTRMLTourmaline Bio1.7574 of 5 stars$13.92-2.5%$54.00+287.9%-66.2%$356.91MN/A-4.9444MBXMBX Biosciences2.59 of 5 stars$10.26-16.9%$37.25+263.1%N/A$342.89MN/A0.0036Insider TradeNews CoverageHigh Trading VolumeCYRXCryoport2.5802 of 5 stars$6.82+0.1%$12.29+80.1%-61.4%$337.11M$233.26M-2.021,170Positive NewsCRVSCorvus Pharmaceuticals1.9049 of 5 stars$5.03-3.5%$12.38+146.0%+82.2%$323.23MN/A-5.4130News CoveragePRMEPrime Medicine2.5319 of 5 stars$2.42-2.0%$13.13+442.4%-65.1%$317.41MN/A-1.18234News CoverageMNPRMonopar Therapeutics0.9208 of 5 stars$51.89+7.1%$43.00-17.1%+1,312.3%$316.53MN/A-26.3410ATYRAtyr PHARMA2.8189 of 5 stars$3.77-3.3%$19.25+410.6%N/A$316.45M$350,000.00-4.0153Analyst ForecastAnalyst RevisionNews CoverageGap Up Related Companies and Tools Related Companies Chimerix Competitors Aurora Cannabis Competitors Annexon Competitors Tourmaline Bio Competitors MBX Biosciences Competitors Cryoport Competitors Corvus Pharmaceuticals Competitors Prime Medicine Competitors Monopar Therapeutics Competitors Atyr PHARMA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ANRO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANRO Stock Alerts